Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor.
Kadri
K
Altundag
Mevlut
M
Kurt
Rabiul
R
Islam
Ozden
O
Altundag
Selahattin
S
Turen
D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D015994:Incidence; D009190:Myelodysplastic Syndromes; D016609:Neoplasms, Second Primary; D017698:Postmenopause; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*
D047072:Aromatase Inhibitors; D020845:Selective Estrogen Receptor Modulators